Management of hairy cell leukaemia in pregnancy.

IF 0.5 Q4 OBSTETRICS & GYNECOLOGY

Obstetric Medicine Pub Date : 2025-08-19 DOI:10.1177/1753495X251356377

Simone Da Cruz, Kylie Mason, William Renwick, Joanne M Said, Briony A Cutts

{"title":"Management of hairy cell leukaemia in pregnancy.","authors":"Simone Da Cruz, Kylie Mason, William Renwick, Joanne M Said, Briony A Cutts","doi":"10.1177/1753495X251356377","DOIUrl":null,"url":null,"abstract":"Background: Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.Methods: A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.Results: Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.Conclusion: Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":" ","pages":"1753495X251356377"},"PeriodicalIF":0.5000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367712/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X251356377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.

Methods: A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.

Results: Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.

Conclusion: Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.

查看原文本刊更多论文

妊娠期毛细胞白血病的处理。

背景：毛细胞白血病（HCL）占所有淋巴样肿瘤的不到1%，在妊娠期很少报道。HCL的管理需要多学科护理，以优化孕产妇和新生儿的结局。方法：检索Ovid MEDLINE和EMBASE中有关“毛细胞白血病”和“妊娠”的文献。结果：回顾了13例，其中3例在我们自己的机构。干扰素- α是n = 3（23%）例患者中不同剂量的最主要治疗方法。其他处理包括产前克拉德滨和利妥昔单抗，产后克拉德滨加和不加利妥昔单抗，腹腔镜脾切除术和终止妊娠。46.1% （n = 6）的患者顺产。由于血小板减少，有更大比例的剖宫产在全麻和一半的病例记录出血并发症。结论：妊娠期HCL诊断和处理困难。妇女可以得到安全的管理，结果目标应该与非怀孕患者相同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetric Medicine OBSTETRICS & GYNECOLOGY-

CiteScore

1.90

自引率

0.00%

发文量